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Memory impairment is a  feature of several diseases and detrimental as aging population have increased worldwide. Sustained 
advanced glycation end products (AGEs) receptor (RAGE) activation triggers the production of reactive oxygen species and 
inflammatory response, leading to neuronal dysfunction and neurodegenerative disorders. Methylglyoxal (MGO) is the most 
relevant and reactive glycating agent in vivo, leading to the formation of AGEs. Here, we investigated the role of RAGE on the memory 
impairment induced by MGO. Swiss female mice were treated for 11 days with MGO, FPS‑ZM1 (a high‑affinity RAGE antagonist), or 
the combination of both. Locomotor activity was not impaired by the treatments, as evaluated by the open field and spontaneous 
alternation test. MGO treatment impaired short‑ and long‑term spatial memory in the object location task, caused deficits on the 
short‑term aversive memory in the step‑down inhibitory avoidance task, and decreased working memory performance as evaluated 
by the Y‑maze spontaneous alternation test. FPS‑ZM1 treatment abolished deficits on the short‑term aversive memory and working 
memory, but was unable to prevent the impairment in short‑term or long‑term spatial memory. Since the addition of RAGE 
antagonist in co‑treatment with MGO protected mice from the aversive and working memory deficits, AGEs generated by the MGO 
treatment would be involved in the memory impairment due to RAGE activation. Therefore, further studies are required to establish 
the involvement of RAGE in the MGO‑induced memory impairment. Nevertheless, our results suggested FPS‑ZM1 treatment as 
a promising new therapeutic strategy to prevent cognitive dysfunction caused by dicarbonyl stress, further investigation is required 
to confirm our findings.
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INTRODUCTION
Aging population has increased worldwide, and 
cognitive dysfunction has become of increasing con‑
cern. Therefore, the development of strategies and 
safe treatments to mitigate cognitive dysfunction are 
needed (Livingston et al., 2017). Likewise, memory im‑
pairment is a feature of several metabolic, genetic and 
degenerative diseases. These different conditions can 
be comorbid, reinforcing each other in augmenting 
cognitive decline, and in some cases, leading to demen‑
tia (Farruggia and Small, 2019; von Arnim et al., 2019).
Methylglyoxal (MGO) is a reactive dicarbonyl gener‑
ated endogenously, mainly by spontaneous dismutation 
of glyceraldehyde‑3‑phosphate and dihydroxyacetone 
phosphate, two intermediary metabolites of glycolytic 
pathway (Thornalley, 1996; 2005). The serum concen‑
tration of MGO in humans was positively associated 
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with poorer memory and executive function, and a fast‑
er rate of cognitive decline (Beeri et al., 2011; Srikanth 
et al., 2013). Moreover, the levels of MGO are elevated in 
patients with mild cognitive impairment (MCI) (Hadd‑
ad et al., 2019). Also, diabetic patients and diabetic rats 
showed elevated MGO in the plasma (Thornalley, 1993; 
Huang et al., 2012; Kong et al., 2014). In this regard, 
about 422 million people have diabetes, with increasing 
numbers globally (WHO, 2020), which is allied to the 
fact that different studies have shown that diabetes can 
lead to cognitive impairment (Biessels et al., 2006; Kodl 
and Seaquist, 2008; Kopf and Frölich, 2009).
Over the past decade, besides diabetes (Matafome 
et al., 2013; Tian et al., 2014), MGO has been linked to 
several conditions, such as cancer (Geng et al., 2014); 
Alzheimer’s disease (Angeloni et al., 2014); hyperal‑
gesia and inflammation (Koivisto et al., 2014); anxiety 
and depression (Distler and Palmer, 2012); and epilepsy 
(McMurray et al., 2014). However, very little is known 
about the mechanisms of action of MGO in the context 
of learning and memory (Watanabe et al., 2014; Schalk‑
wijk and Stehouwer, 2020).
MGO is the most relevant and reactive glycating 
agent in vivo, leading to the formation of advanced gly‑
cation end products (AGEs) (Thornalley, 2005). MGO re‑
acts with amino groups of basic amino acids of proteins, 
causing a loss of positive charges and promptly leading 
to the formation of hydroimidazolones (Thornalley, 
2008; Xue et al., 2014). Hydroimidazolone adducts gen‑
erated by MGO are physiological ligands of the receptor 
for AGEs (RAGE) (Xue et al., 2014). Since potential an‑
ti‑AGEs drugs and their mechanisms of action have not 
been elucidated, it highlights the importance for inves‑
tigating the effects of MGO burden on RAGE modulation 
(Toprak and Yigitaslan, 2019).
RAGE belongs to the immunoglobulin superfamily 
and is expressed on the surface of astrocytes, neurons 
and microglia (Gonzalez‑Reyes and Rubiano, 2018; Pal‑
anissami and Paul, 2018). RAGE contains an extracel‑
lular V domain that binds multiple ligands, including 
AGEs, beta‑amyloid (Aβ) protein, and high‑mobility 
group box‑1 (HMGB1). Sustained RAGE activation by 
AGEs leads to reactive oxygen species (ROS) production 
and inflammatory response, which are associated with 
neuronal dysfunction and neurodegenerative disorders 
(Sorci et al., 2013; Cai et al., 2016; Kay et al., 2016; Pala‑
nissami and Paul, 2018). Therefore, preclinical and clini‑
cal studies have pointed out that drugs capable of block‑
ing RAGE may be useful as therapeutic tools, able to 
alleviate cognitive dysfunction of Alzheimer’s disease 
patients (Yamagishi et al., 2008; Deane et al., 2012; Cai et 
al., 2016; Hong et al., 2016). Moreover, memory deficits 
induced by the treatment with HMGB1 were prevented 
in RAGE knockout mice (Mazarati et al., 2011).
FPS‑ZM1 is a high‑affinity RAGE antagonist, perme‑
able to the blood‑brain barrier that binds to the V do‑
main of RAGE. In rodents, FPS‑ZM1 was able to inhibit 
RAGE‑mediated influx of circulating Aβ40 and Aβ42 into 
the brain (Deane et al., 2012). In addition, FPS‑ZM1 in‑
hibited β‑secretase activity, thus, decreasing Aβ forma‑
tion, microglia activation and inflammatory respons‑
es. Nevertheless, results from different models have 
shown that FPS‑ZM1 can be beneficial. Treatment with 
FPS‑ZM1 was effective in normalizing cognitive per‑
formance in APPsw/0 transgenic mouse model of Alzhei‑
mer’s disease and in an AGEs‑RAGE activated rat model 
(Deane et al., 2012; Hong et al., 2016). Also, FPS‑ZM1 can 
decrease cell infiltration and edema in a model of brain 
hemorrhage, decreasing oxidative and cellular damage 
to the renal tubule (Deane et al., 2012; Li et al., 2015; 
Hong et al., 2016; Lian et al., 2017; Sanajou et al., 2019).
In a previous work, we demonstrated that repeated 
MGO (50 mg/kg) treatment, for 11 days by systemic in‑
jection, caused extensive memory impairment in mice 
(Szczepanik et al., 2020). In order to investigate wheth‑
er memory impairment induced by MGO was depen‑
dent on RAGE activation, mice were treated with the 
RAGE antagonist FPS‑ZM1 in co‑administration with 
MGO for 11 days.
METHODS
Animals and treatments
Experiments were conducted using 3‑month‑old 
female Swiss mice (35‑55 g) bred at the Federal Uni‑
versity of Santa Catarina (UFSC), Florianópolis, Brazil. 
Mice were maintained in groups of 7‑10 animals per 
cage (42 × 34 × 17 cm), under controlled temperature 
(22±1°C), and 12 h light cycle (lights on at 7:00 AM), 
with free access to food (standard chow diet) and water. 
Efforts were made to minimize the number of animals 
used and their suffering.
We used mice of the same age and sex that were in‑
vestigated in our previous treatment protocol (Szcze‑
panik et al., 2020). Older age is a primary risk factor for 
cognitive decline, and cognitive dysfunction in healthy 
young humans is a rare condition (Carpenter et al., 
2019). Therefore, we aimed to investigate the MGO‑in‑
duced memory impairment on the adulthood. We 
choose mice of 3 months old (90 days) in the beginning 
of the treatments (day 0). Considering life stages of 
Mus musculus, 3 months old mice over our experimental 
protocol of 13 days resembled equivalent to 27‑32 years 
old in human age (Dutta and Sengupta, 2016). 
Female subjects are underrepresented in pre‑clini‑
cal research, particularly in the field of neuroscience 
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where it is found over five studies on males for each 
study on females (Beery, 2018). Since female rodents 
are not more variable than males, and, given the lack 
of studies using female subjects, we decided to investi‑
gate female mice, which will likely result better under‑
standing of female, and eventually, translate to better 
treatment outcomes for women, as indicated by others 
(Prendergast et al., 2014; Beery, 2018).
MGO (pyruvaldehyde) (CAS Number: 78‑98‑8) was 
purchased from Sigma‑Aldrich (São Paulo, Brazil), 
and FPS‑ZM1 [4‑chloro‑N‑cyclohexyl‑N‑(phenylmeth‑
yl)‑benzamide] (#6237, CAS Number: 945714‑67‑0), was 
purchased from Tocris Bioscience (São Paulo, Brazil). 
Mice were treated with 0.9% saline (vehicle: control); 
20 or 50 mg/kg MGO; 2 mg/kg FPS‑ZM1 diluted in ve‑
hicle, or the co‑administration of MGO and FPS‑ZM1. 
The FPS‑ZM1 dose chosen was based upon two previ‑
ous studies (Deane et al., 2012; Lian et al., 2017). The 
drugs were administered by intraperitoneal injection 
(i.p.) with a relative injection volume of 1 ml / 100 g of 
body weight.
Each mouse received two i.p. injections on con‑
tralateral sides each day, during 11 days, making up 
the following groups: saline + saline (control), saline 
+ MGO, FPS‑ZM1 + saline, or FPS‑ZM1 + MGO (N=7‑10 
animals per group). To evaluate the effects of repeat‑
ed treatment with FPS‑ZM1 and MGO, behavioral tests 
were performed at indicated time points, always 24 h 
after the last MGO injection (Fig. 1), as follows: han‑
dling (day 0); administration of MGO (days 1‑11); open 
field (day 5); object location task (days 5‑9); Y‑maze 
spontaneous alternation (day 10); step‑down inhibito‑
ry avoidance task (day 11). To avoid acute effects and 
possible withdrawal syndrome, mice were treated with 
MGO 2 h after the behavioral testing.
To test the acute effect, an independent cohort of 
mice received a single injection of MGO (20 mg/kg) and/
or FPS‑ZM1 (2 mg/kg) to investigate spatial short‑term 
memory using the object location task.
In all treatments, the RAGE antagonist FPS‑ZM1 
was injected prior to MGO, following a 30 min interval 
between injections.
Experimental procedures
All the procedures used in this study were autho‑
rized and complied with the guidelines on the animal 
care of the UFSC Ethics Committee on the Use of Ani‑
mals (CEUA/UFSC, protocol number: 7245210616), a lo‑
cal committee which follows the “ARRIVE guidelines” 
and the “Guide for the Care and Use of Laboratory An‑
imals” from NIH. Behavioral tests were conducted be‑
tween 09:30 and 16:30 h in a dimly lit and sound‑iso‑
lated room: 15 lx for the open field and object location 
task; 30 lx for the remaining behavioral tests. The ex‑
periments were recorded by a video camera system and 
images analyzed using the ANY‑maze® software (Stoelt‑
ing Co., Wood Dale, IL, USA). Mice were acclimatized 
to the experimental room for 2 h before the beginning 
of the tests. Once the mouse was exposed to a session 
paradigm, it was not mixed with non‑exposed mice on 
its return to the home cage. In the acute treatments, 
an independent group of mice was used for the object 
location task. The total number of mice used in the be‑
havioral tests was 52. 
Open field 
The spontaneous locomotor activity and anxi‑
ety‑like behavior of mice were evaluated in an open 
field arena. In the experiment, each animal was placed 
in the center of the arena to freely explore the appara‑
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Fig. 1. Schematic representation of repeated treatment and behavioral tests. Mice were subjected to repeated treatment with saline (control), methylglyoxal 
(MGO), FPS‑ZM1 (ZM1) or MGO + ZM1 once a day for 11 days by i.p. injection. Mice were tested in the OF (day 5), OLT (days 5‑9), SA (day 10), and step‑down 
inhibitory avoidance task (SDT, day 11).
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tus for 5 min. The apparatus was made of four transpar‑
ent acrylic walls (30 cm high) and gray floor of 40 cm × 
40 cm. The parameters analyzed were the total distance 
traveled (m), average speed (m/min), the number of en‑
tries and time spent (s) by the mouse in the central area 
(20 × 20 cm) of the open field arena (Belzung, 1999).
Object location task 
The spatial memory of mice was assessed using the 
object location task (OLT) to evaluate both short‑ and 
long‑term memory. Evaluation of short‑term memory 
was carried out based on a previous protocol (Assini et 
al., 2009). In this paradigm, each mouse was habituated 
in the open field arena with transparent walls for 5 min 
(habituation session). Twenty‑four hours thereafter, 
mice were placed in the same arena for 5 min facing 
two identical objects (5 × 3 cm; training session). Nine‑
ty minutes after training, one of the objects was moved 
to a new location (test session), and the time spent ex‑
ploring the objects in new (novel) and old (familiar) 
locations were recorded for 5 min. The two identical 
objects were placed 20 cm apart, 7 cm away from the 
walls, and the relative position of the relocated object 
was counterbalanced among the mice. Visual cues were 
added in the test room to serve as spatial reference. In 
order to analyze the cognitive performance, a location 
index was calculated: (Tnovel × 100)/(Tnovel + Tfamiliar), where 
Tnovel is the time spent exploring the relocated object 
and Tfamiliar is the time spent exploring the non‑relocat‑
ed object (Vogel‑Ciernia and Wood, 2014).
Using the above protocol, we tested an acute admin‑
istration, as follows: after habituation session on the 
previous day, mice received an i.p. injection of 0.9% 
saline or FPS‑ZM1 (2 mg/kg); 30 min after that, the 
mice received an i.p. injection of 0.9% saline or MGO 
(20 mg/kg), making up the following groups: saline + 
saline (control); saline + MGO (MGO); and FPS‑ZM1 + 
MGO. Then, 2 h after the last injection, mice were sub‑
mitted to the training session (5 min), and returned to 
home cage. Finally, 90 min after the training session 
(3.6 h after MGO administration), the test session was 
performed for 5 min to evaluate short‑term memory. 
Also, the effects of repeated treatments were 
evaluated 4 days after a pretreatment with MGO 
(50 mg/kg, i.p.), using a modified protocol to evaluate 
the long‑term type of spatial memory. This protocol 
included 3 days of habituation during 5 min sessions 
(1 session per day), with the open field floor covered 
with wood shavings. This was followed by MGO admin‑
istration 2 h later. On the 4th day, a training session 
was performed for 10 min, which was followed by MGO 
administration 2 h after training. The test session of 
5 min was performed 24 h after the training session 
(Vogel‑Ciernia and Wood, 2014).
Spontaneous alternation 
Evaluation of working memory of mice was carried 
out measuring the spontaneous alternation (SA) rate 
in a Y‑maze, which was positively related to better 
memory performance. When moving from one place 
to another, rodents exhibit the natural tendency to 
explore the least visited area or a previously known 
area which has changed (novelty), this behavior is 
referred to as spontaneous alternation (Tolman, 
1925). Spontaneous alternation was assessed using 
a Y‑shaped maze, made of opaque gray acrylic, with 
three equal arms (30 cm length, 10 cm width, 25 cm 
height), disposed at 120° from each other and con‑
nected by a triangular central area (neutral zone). In 
the test, each mouse was placed in the neutral zone 
and allowed to explore the maze area for 5 min. An 
arm entry was computed only when the mouse en‑
tered with all four paws. The total number of arm en‑
tries (N) was used as a parameter of locomotor activ‑
ity. The number of ‘correct’ triplets (M, consecutive 
choices of each of the three arms without re‑entries) 
was also registered. Based on the ‘correct’ triplets, 
the spontaneous alternation rate was computed ac‑
cording to the formula: R(%) = M × 100/(N−2) and used 
as parameter of cognitive performance (Dember and 
Fowler, 1958; Kleschevnikov et al., 2017).
Step‑down inhibitory avoidance task 
To assess short‑term aversive memory, mice were 
exposed to the step‑down inhibitory avoidance task 
(SDT). The apparatus was a 23 × 21 × 21 cm3 box made 
of acrylic and steel in which the floor was composed 
of a parallel grid of stainless‑steel bars with 4 mm di‑
ameter spaced 1 cm apart. A vinyl platform (11 × 8 cm 
wide, 3 cm high) was placed in the center of the floor. 
Based on previously described procedures (Roesler et 
al., 1999; Moreira et al., 2012), each mouse was placed 
on the platform and its latency to step down on the 
grid with all four paws was measured. During the 
training session, immediately after stepping down on 
the grid, the mouse received a 2 s long scrambled foot 
shock (0.3 mA), then it was transferred to its home 
cage. This task is based on the mice’s avoidance be‑
havior to step down the platform after receiving the 
electric shock. To evaluate memory retention, a test 
session was performed 1.5 h after the training session. 
The test session was identical to the training session, 
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except that no foot shock was given. A maximum of 
180 s per session was waited to the mouse stepping 
down on the grid. 
Statistical analysis
Statistical analyses were performed using one‑way 
or two‑way analysis of variance (ANOVA), appropriate 
in each case, followed by the Newman‑Keuls post hoc 
test. Additional analysis were made for the OLT using 
Student’s t‑test to compare the location index values 
with the random chance of 50%, related to the explora‑
tion time of the two objects in the task. In the SDT, pre‑
senting non‑normal distribution, statistical analysis 
was performed using the Kruskal‑Wallis non‑paramet‑
ric test followed by Dunn’s comparison. The accepted 
level of statistical significance was P≤0.05. Data are ex‑
pressed as mean ± standard error of the mean (SEM) or 
median (interquartile range). All statistical tests were 
carried out using the Statistica software package, ver‑
sion 7.0 (StatSoft Inc., Tulsa, OK, EUA).
RESULTS
Effects on locomotor activity
Mice were submitted to the open field on the 5th 
treatment day. One‑way ANOVA revealed no statisti‑
cally significant differences in the total distance trav‑
elled (F3,18=0.447, P>0.05) (Fig. 2A), the average speed 
(F3,18=0.447, P>0.05) (Fig. 2B), and the number of en‑
tries (F3,18=1.057, P>0.05) (Fig. 2C) and the time spent 
(F3,22=0.541, P>0.05) (Fig. 2D) in the central area of the 
open field apparatus.
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Fig. 2. Locomotor activity of mice after repeated treatment with methylglyoxal and FPS‑ZM1. Mice were treated for 4 days with methylglyoxal (MGO, 
50 mg/kg) or FPS‑ZM1 (ZM1, 2 mg/kg) or with co‑administration (ZM1 + MGO). Twenty‑four hours after the last dministration, mice were evaluated for 
5 min in the open field. A) Distance traveled (m); B) Average speed (m/min); C) Number of entries, and D) Time spent in the central area. The bars represent 
the mean ± SEM of 6‑7 animals per group. No statistical differences among groups were found.
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RAGE inhibitor FPS‑ZM1 does not rescue spatial 
memory impairment induced by MGO
Mice were tested in the OLT to assess the spatial 
memory, on the 9th treatment day. Mice were submitted 
to the open field for 3 days for habituation purpose, 
and 24 h after the training session, long‑term memory 
was evaluated (Fig. 3A). One‑way ANOVA followed by 
the Newman‑Keuls test revealed that the groups MGO 
and FPS‑ZM1 + MGO showed lower location index when 
compared to the control group (F3,24=7.492, P<0.05), in‑
dicating memory impairment. However, the FPS‑ZM1 
group showed similar location index in comparison to 
the control group (F3,24=7.492, P<0.05), indicating ab‑
sence of memory impairment. When the groups were 
compared against the random chance of exploring both 
objects equally (50%), results were confirmed, as well. 
Control (t6=5.173, P<0.05) and FPS‑ZM1 (t6=14.57, P<0.05) 
groups explored the relocated object B for more than 
50% of the total exploration time, thereby, showing 
memory retention. Mice treated with MGO (t6=0.826, 
P>0.05), or FPS‑ZM1 + MGO (t6=1.059, P>0.05) did not 
present significant differences in the object location 
index, when compared to 50%, indicating memory im‑
pairment (Fig. 3A). In the training session, no differ‑
ences among the groups were found between the two 
identical objects exploration period (Fig. 3C). Two‑way 
ANOVA revealed no significant differences to treat‑
ment (F3,48=1.974, P>0.05), or object factors (F1,48=0.084, 
P>0.05). Also, no significant interaction between treat‑
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Fig. 3. Spatial memory in the OLT of mice treated with methylglyoxal and FPS‑ZM1. Mice were treated for 7 days with methylglyoxal (MGO), FPS‑ZM1 (ZM1, 
2 mg/kg), or with both (ZM1 + MGO) and evaluated in OLT. Long term (A) or short term (B) memory was evaluated 3.6 or 24 h after the last MGO injection 
with 20 or 50 mg/kg, respectively. The bars represent the mean ± SEM (n=7‑8 animals per group). * P<0.05 (Student’s t‑test, as compared to 50%; and 
Newman‑Keuls post hoc test).
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ment and exploration time of the two objects was re‑
vealed (F3,48=0.151, P>0.05). Therefore, it indicates no 
bias due to a possible exploratory preference in the 
training session.
We have already demonstrated in our previous 
work that MGO (20 mg/kg, i.p.) induced impairment 
in short‑term spatial memory after a single acute in‑
jection. In order to investigate whether this effect 
can be prevented by FPS‑ZM1, an independent co‑
hort of mice was treated once with MGO (20 mg/kg); 
or FPS‑ZM1 (2 mg/kg) + MGO (20 mg/kg). To evaluate 
the short‑term spatial memory, mice were tested in 
the OLT 90 min after the training session, and 3.6 h 
after MGO injection. In this case, results showed that 
FPS‑ZM1 was also unable to prevent the impairment 
induced by MGO on spatial memory (Fig. 3B). One‑way 
ANOVA followed by the Newman‑Keuls test revealed 
that only the control group (F2,19=2.343, P<0.05) showed 
significant difference on the location index, indicat‑
ing memory retention. The control mice explored the 
object B (relocated) for a significantly longer period 
(t7=2.561, P<0.05), when compared to 50%. However, 
mice treated with MGO (t6=0.944, P>0.05) and FPS‑ZM1 
+ MGO (t6=0.503, P>0.05) showed no differences re‑
garding a random preference of 50%, thus, indicating 
memory impairment. In the training sessions, two‑way 
ANOVA revealed that the same mice explored the ob‑
jects (A and B) for a similar period. No differences were 
found for treatment (F2,42=0.826, P>0.05), relative explo‑
ration of the objects (F1,42=1.732, P>0.05), or interaction 
between treatment and exploration time (F2,42=0.146, 
P>0.05) (Fig. 3D).
RAGE inhibitor FPS‑ZM1 prevent working memory 
deficit induced by MGO
Working memory of mice was evaluated after re‑
peated treatment with MGO for 10 days, according 
to the spontaneous alternation rate, as evaluated 
by recording the arm entries in the Y‑maze (Fig. 4). 
One‑way ANOVA, followed by the Newman‑Keuls test, 
revealed that mice treated with MGO showed signifi‑
cantly decreased alternation rate, when compared 
to the control, and the other groups, indicating defi‑
cit on the working memory performance (F3,24=7.734, 
P<0.05). Treatment with FPS‑ZM1 did not change the 
alternation rate in the Y‑maze, as compared to the 
control group (P>0.05). Interestingly, results suggested 
that FPS‑ZM1 administration prevented the working 
memory deficit induced by MGO, as significant differ‑
ence was not observed in the FPS‑ZM1 + MGO group, 
in comparison to the control group (P>0.05) (Fig. 4A). 
One‑way ANOVA failed to indicate differences on the 
total number of arm entries (F3,24=1.910, P>0.05), indi‑
cating locomotor activity of mice was not altered by 
the treatments (Fig. 4B). Also, it indicates no biases 
due to any locomotor effect.
RAGE inhibitor FPS‑ZM1 prevent short‑term 
aversive memory impairment induced by MGO
The SDT was used to evaluate short‑term aversive 
memory on 11th day of treatment. Mice were tested 
1.5 h after the training (learning) session, in which 
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Fig. 4. FPS‑ZM1 prevented working memory deficit in mice treated with MGO. Mice were treated for 9 days with methylglyoxal (MGO, 50 mg/kg), FPS‑ZM1 
(ZM1, 2 mg/kg), or with both (ZM1 + MGO), and 24 h after the last administration, evaluated in the Y‑maze: A) Alternation rate (%), as a measure of working 
memory; B) Number of arm entries, as a measure of locomotor activity. The bars represent the mean ± SEM of 7 animals per group. * P<0.05 compared 
to the control group; # P<0.05 compared to the MGO group (Newman‑Keuls post hoc test).
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they received an electrical stimulus. The latency time 
to step‑down from the platform was measured in 
both sessions. The Kruskal‑Wallis analysis was signif‑
icant (Chi‑square=35.22, P<0.05), which was followed 
by Dunn’s comparison and observed by the differ‑
ence in rank sum (R diff). The control group present‑
ed a significantly longer latency time to step‑down 
from the platform in the test session, when compared 
to its respective latency time in the training session 
(R diff=‑23.67, P<0.05), indicating memory retention. 
However, results revealed that mice treated with MGO 
was unable to show increased latency time in the test 
session, when compared with its respective latency 
time in the training session (R diff=‑16.50, P>0.05). This 
result indicates short‑term aversive memory deficit 
caused by MGO. Unlike the MGO group, mice treated 
with FPS‑ZM1 (R diff=‑25.58, P<0.05) and FPS‑ZM1 + 
MGO (R diff=‑27.79, P<0.05), presented increased laten‑
cy to step down, indicating memory retention. Once 
the FPS‑ZM1 + MGO group showed increased latency 
time in the test session, this indicates that FPS‑ZM1 
was able to prevent the short‑term memory impair‑
ment induced by MGO (Fig. 5).
DISCUSSION
RAGE effects are strongly dependent on the cell 
type and physiological conditions, and involved in 
tissue homeostasis and regeneration following injury 
(Sorci et al., 2013). It is already known that activation 
of RAGE by AGEs can lead to oxidative stress and altered 
gene expression (Wautier et al., 2001; Palanissami and 
Paul, 2018). Since MGO is the most reactive glycating 
agent leading to the formation of AGEs, it is thought to 
be a major RAGE ligand (Thornalley, 2005). Cognitive 
dysfunction can be triggered by ROS, inflammatory re‑
sponse and neuronal dysfunction after sustained RAGE 
activation (Cai et al., 2016; Kay et al., 2016). AGEs/RAGE 
signaling can be involved in the vascular complication 
of diabetes, leading to a variety of neuropathies, cogni‑
tive dysfunction and accelerated atherosclerosis, which 
could account for disabilities and high mortality rates 
in diabetic patients (Kodl and Seaquist, 2008; Yamagishi 
et al., 2008). In line with this idea, we treated young 
mice for 11 days with MGO and detected a clear cogni‑
tive impairment. Here, it is shown that a high‑affinity 
RAGE antagonist (FPS‑ZM1) can prevent some memory 
impairments induced by MGO.
Results showed that the treatments did not affect the 
locomotor activity or anxiety‑like behavior of mice, as 
evaluated in the open field, OLT and SA, indicating that 
the memory dysfunction observed were independent of 
these factors. Since MGO has already been associated 
with locomotor depression and decreased anxiety‑like 
behavior (Hovatta et al., 2005; Distler et al., 2012), these 
were relevant features to be accessed.
Evaluation of cognitive parameters showed that 
FPS‑ZM1 alone did not cause any memory deficit. How‑
ever, MGO treatment impaired short‑ and long‑term 
spatial memory in the OLT, short‑term aversive mem‑
ory in the SDT, and decreased working memory per‑
formance of mice in the SA. All of these results cor‑
roborate our previous data obtained from the same 
experimental approach. Also, we observed that mice 
treated with MGO displayed increased depressive‑like 
behavior, along with dopamine depletion in the cere‑
bral cortex (Szczepanik et al., 2020). Depressive‑like be‑
havior have been associated with neuronal atrophy and 
synaptic loss in the cortex and hippocampus, which are 
neuroplasticity impairments involved in memory dys‑
function (Price and Duman, 2020). Especially, depres‑
sive behaviors and anhedonia are hardly dissociated 
from learning and memory disorders in humans, and 
cognitive impairment is a hallmark of major depressive 
disorder (Baune and Renger, 2014). Thus, this is in line 
with our results from the memory tests.
Behavioral memory tests can be biased by non‑mne‑
monic factors, such as arousal level, sensory sensitivity 
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Fig.  5. FPS‑ZM1 prevented the aversive memory impairment in mice 
treated with MGO. Mice were treated for 10  days with methylglyoxal 
(MGO, 50 mg/kg), FPS‑ZM1 (ZM1, 2 mg/kg) or with both (ZM1 + MGO), and 
evaluated in the SDT, 24 h after the last MGO administration. Short‑term 
memory was evaluated 1.5 h after the training session that consisted of 
an aversive electrical stimulus, but without applying this stimulus. The 
bars represent the median (interquartile range) of step‑down latencies of 
6‑7 animals per group. * P<0.05 as compared to the training session of 
the same group (Kruskal‑Wallis non‑parametric test followed by Dunn’s 
comparison).
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and random agents (Robinson et al., 2019). In order to 
draw deeper conclusions from our experiments, other 
behavioral learning and memory tests (such as radial 
arm maze and Morris water maze) would be helpful. 
Other tests can provide complementary results regard‑
ing the degree of acquisition and expression of memo‑
ry, as well as to evaluate other memory domains (Vor‑
hees and Williams, 2006). Moreover, our 11‑day treat‑
ment cannot establish the potency and duration of the 
effects of FPS‑ZM1 or MGO, beyond the study period. 
Therefore, multiple trial tests, longer treatment peri‑
ods and using pharmacological tools would be neces‑
sary to examine more deeply the effects of FPS‑ZM1 and 
MGO on memory. For instance, spatial memory was not 
protected by FPS‑ZM1 in MGO‑treated mice, in acute or 
repeated regimen, suggesting action mechanisms other 
than RAGE activation would take place.
Most of the anti‑RAGE antibodies available block 
only peripheral RAGE, and do not cross the blood‑brain 
barrier. In addition, they may have toxic effects at 
therapeutic doses. On the other hand, FPS‑ZM1 is per‑
meable to the blood‑brain barrier, where off target ef‑
fects were evaluated in cell culture, and in mice up to 
a dose of 500 mg/kg (i.p.). Physiological parameters or 
susceptibility to infection were not altered in rodents 
treated with FPS‑ZM1 (Deane et al., 2012). Previously, 
it was demonstrated that RAGE‑neutralizing antibodies 
protected human SH‑SY5Y neuroblastoma cells, and rat 
cortical neurons from oxidative stress and cell death in‑
duced by AGEs, in a model using glycated bovine serum 
aluminum (Yin et al., 2012). In the present study, we 
found that systemic injection of FPS‑ZM1, in co‑treat‑
ment with MGO, protected mice from deficits on the 
short‑term aversive and working memory, despite its 
ineffectiveness toward spatial memory impairment. 
Based on the FPS‑ZM1 positive effects on memory, we 
speculate that drugs, such as perindopril (increases the 
soluble form of RAGE) and alagebrium (cleaves AGEs 
cross‑links), would be effective in preventing memory 
dysfunction. Actually, it was already shown that de‑
creasing the AGEs/RAGE signaling can prevent work‑
ing memory decline in diabetic rats, as evaluated in the 
Y‑maze (Zakaria et al., 2015).
Activation of RAGE triggers the production of ROS 
via NADPH oxidase, and the activation of the transcrip‑
tion factor nuclear factor kappa B (NFκB), which leads 
to increased levels of pro‑inflammatory cytokines 
(Sorci et al., 2013; Palanissami and Paul, 2018). Since 
the activation of RAGE positively modulates its own ex‑
pression via NFκB responsive element (Schleicher and 
Friess, 2007; Fang et al., 2010), repeated MGO treatment 
would amplify the AGEs/RAGE signaling, potentially 
contributing to the cognitive impairment observed in 
mice. In agreement with this hypothesis, the protec‑
tive effects of FPS‑ZM1 against MGO‑induced cogni‑
tive dysfunction can be recognized from other stud‑
ies. After FPS‑ZM1 treatment, streptozotocin‑induced 
diabetic rats showed attenuated renal expressions of 
tumor necrosis factor‑alpha (TNF‑α) and interleukin‑6 
(IL‑6) (Sanajou et al., 2019), two cytokines also linked 
to neuroinflammation (Becher et al., 2017). Moreover, 
FPS‑ZM1 attenuated diabetes‑induced elevations in 
renal levels of RAGE and phosphorylated NFκB p65 
subunit (Sanajou et al., 2018). In aorta of aged rats, 
FPS‑ZM1 reduced ROS and IL‑6 levels, and suppressed 
the activation of NFκB (Gu et al., 2014). Other studies 
also corroborate this notion, for instance, the over‑
expression of microglial RAGE in transgenic mice ex‑
pressing the mutant human amyloid precursor protein 
(mAPP), implicated in the pathogenesis of Alzheimer’s 
disease, increased the production of pro‑inflammato‑
ry mediators such as TNF‑α, interleukin 1 beta (IL‑1β), 
the infiltration of microglia and astrocytes, the accu‑
mulation of Aβ peptide, and accelerated the appear‑
ance of deficits on learning and spatial memory (Fang 
et al., 2010). Accordingly, the downregulation of RAGE 
by β‑asarone was linked to memory improvement in 
a double transgenic mouse model of Alzheimer’s dis‑
ease (Yang et al., 2016). Moreover, the downregulation 
of both RAGE and NFκB by the Panax ginseng extract 
was associated to the protection of long‑term spatial 
and aversive memory in a model of AGEs production 
in rats (Tan et al., 2015). All the findings, along with 
the behavioral evidences presented by this study using 
MGO treatment, suggest that the depression of AGEs/
RAGE signaling in critical stressed tissues can result 
in better outcomes in cases of impaired learning and 
memory function.
CONCLUSIONS
Overall, our results suggest that FPS‑ZM1 treatment 
could potentially be used to prevent cognitive dysfunc‑
tion caused by dicarbonyl stress. For the establishment 
of FPS‑ZM1 as a valid new therapeutic tool, further 
studies will be needed. Differences in the experimen‑
tal conditions (species, behavioral tests, and dose vs. 
treatment period), could modify FPS‑ZM1 effectiveness 
in preventing MGO‑induced responses in mice. Inves‑
tigating the balance between different doses of MGO 
and FPS‑ZM1 and dose‑response effects are necessary. 
Nevertheless, evaluating different ages, treatment reg‑
imens and long‑term effects are also interesting top‑
ics for future studies. Since we used only Swiss female 
mice in this study, other studies using male subjects 
would be also necessary, as well as studying other mice 
strains. Thus, future studies could consolidate the ben‑
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eficial effects of FPS‑ZM1 against the cognitive dys‑
function caused by MGO.
In conclusion, results showed that MGO treatment 
impaired working memory, short‑ and long‑term mem‑
ory. Furthermore, data presented by this study are ex‑
perimental evidence that FPS‑ZM1 protected mice from 
the short‑term aversive and working memory deficits 
induced by MGO. Finally, results suggested that RAGE 
activation was involved, at least in part, in the ob‑
served memory impairment. However, this was not the 
case for long‑term spatial memory, indicating further 
studies are required to address the exact mechanisms 
responsible for MGO‑induced cognitive dysfunction.
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